Hybrid nanocrystals: achieving concurrent therapeutic and bioimaging functionalities toward solid tumors.

Area of Science:

• Nanotechnology
• Materials Science
• Pharmacology

Background:

• Developing effective drug delivery systems is crucial for cancer therapy.
• Nanomaterials offer unique properties for targeted drug delivery and bioimaging.
• Paclitaxel is a widely used chemotherapy drug with limitations in delivery and efficacy.

Purpose of the Study:

• To synthesize and characterize hybrid nanocrystals for combined bioimaging and cancer therapy.
• To evaluate the in vivo biodistribution and tumor accumulation of these hybrid nanocrystals.
• To assess the potential of hybrid nanocrystals as a sustained drug delivery platform for anticancer treatment.

Main Methods:

• Synthesis of solid, nanosized paclitaxel crystals incorporating fluorescent molecules.
• Intravenous administration of hybrid nanocrystals to tumor-bearing mice.
• In vivo bioimaging to track nanocrystal localization and retention in tumors.
• Evaluation of nanocrystal accumulation in ectopic tumors.

Main Results:

• Hybrid nanocrystals successfully incorporated fluorescent molecules within the paclitaxel crystal lattice.
• Nanosized paclitaxel crystals retained fluorescence in the solid state.
• Significant accumulation of hybrid nanocrystals was observed in solid tumors.
• The nanocrystals demonstrated prolonged retention within the tumor microenvironment for several days.

Conclusions:

• Hybrid nanocrystals represent a promising platform for simultaneous bioimaging and therapeutic delivery.
• The targeted accumulation and sustained release of paclitaxel from these nanocrystals could enhance therapeutic outcomes.
• Further investigation is warranted to confirm the anticancer efficacy of these novel hybrid nanocrystals.